The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of trifluridine/tipiracil (FTD/TPI) in recurrent/metastatic nasopharyngeal (r/m NPC) carcinomas with or without prior exposure to fluoropyrimidines.
 
Jia Li Low
Travel, Accommodations, Expenses - astrazeneca
 
Wan Qin Chong
No Relationships to Disclose
 
Edwin Pun Hui
Consulting or Advisory Role - MSD
Research Funding - MSD Oncology (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - MSD
 
Winky Lai
No Relationships to Disclose
 
Candice Le
No Relationships to Disclose
 
Kenneth Sooi
No Relationships to Disclose
 
Robert John Walsh
No Relationships to Disclose
 
Anthony T. C. Chan
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Merck Sharp & Dohme
Research Funding - Angene Biotechnology (Inst); Merck Sharp & Dohme (Inst); NRG Oncology (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Roche
 
Boon C. Goh
Stock and Other Ownership Interests - Gilead Sciences; Regeneron; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Honoraria - Amgen; MSD Oncology; Novartis
Consulting or Advisory Role - Adagene; Bayer; Novartis; Otsuka; Pfizer
Research Funding - Adagene (Inst); ALX Oncology (Inst); Bayer; Bristol-Myers Squibb/Medarex (Inst); Genentech/Roche; Kyowa Hakko Kirin; MSD Oncology (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Detection of biomarkers for NSCLC SG Patent no 10201811119X granted EU patent no 19894719.4 published 20 Oct 2021 Modulation of Signal Transducer and Activator of Transcription 3 (STAT3) Expression Patent Pending SG2021/050462; Detection of biomarkers for NSCLC SG Patent no 10201811119X granted EU patent no 19894719.4 published 20 Oct 2021 Modulation of Signal Transducer and Activator of Transcription 3 (STAT3) Expression Patent Pending SG2021/050462
 
Brigette Ma
Honoraria - AstraZeneca; Daiichi Sankyo; Merck Serono; MSD; MSD; Taiho Pharmaceutical; Y-Biologics
Consulting or Advisory Role - Alentis Therapeutics; AstraZeneca; Merck Sharp & Dohme; Pierre Fabre; Viracta Therapeutics; Y-biologics
Research Funding - Merck Serono
Travel, Accommodations, Expenses - Merck Serono